NEW TECHNOLOGY TO HELP BREAST CANCER SURVIVORS GOES GLOBAL
Published Wednesday, 18 June, 2008 at 08:49 AM
Premier
The Honourable Anna Bligh
SAN DIEGO: Premier Anna Bligh today opened the new US headquarters of a Brisbane-based company pioneering technology to help breast cancer survivors.
ImpediMed is gearing up to launch the L-Dex U400 globally in late 2008, a device to provide the early assessment and detection of lymphoedema for medical professionals.
Lymphoedema is a condition that affects more than 100,000 women recovering from breast cancer in Australia alone.
Queensland Premier Anna Bligh, who officiated at today’s opening, said the technology behind the L-Dex U400 was developed by researchers at the Queensland University of Technology and the University of Queensland.
“This is a significant breakthrough in the early detection of an often painful and incurable side effect suffered by breast cancer survivors and indeed many other patients recovering from surgeries and a host of other conditions,” she said.
“In fact there are about 300,000 people in Australia with some form of lymphoedema, with worldwide sufferers currently estimated at around 120 million.
“The condition can be irreversible if not detected early.
The early detection and treatment of lymphoedema can make a significant difference in preventing progression to irreversible stages. This can significantly improve the quality of life of patients and that is why there is considerable interest in this technology.”
Ms Bligh said the device was expected to receive FDA clearance this year and was receiving strong support from cancer specialists across the country.
“ImpediMed’s success is a great testament to Queensland’s growing expertise in the area of medical device development,” she said.
“Queensland’s therapeutic medicines and devices sector is an important economic sector for the Smart State.”
ImpediMed is already a leader in the field of bioimpedance to measure shifts in body fluid status for applications such as lymphoedema, oedema and therapeutic dosing.
The company recently acquired the American medical device company Xitron and will now continue the expansion of its design, service and manufacturing sections in the US – which is expected to generate 90 per cent of its future revenue.
ImpediMed has received $115,500 in grant assistance from the Queensland Government.
Contact: Premier’s office 3224 4500
Company contact: ImpediMed, Greg Brown, CEO, AU Mobile +61 408 2811 27, US Mobile +1 858 537 7612
ImpediMed is gearing up to launch the L-Dex U400 globally in late 2008, a device to provide the early assessment and detection of lymphoedema for medical professionals.
Lymphoedema is a condition that affects more than 100,000 women recovering from breast cancer in Australia alone.
Queensland Premier Anna Bligh, who officiated at today’s opening, said the technology behind the L-Dex U400 was developed by researchers at the Queensland University of Technology and the University of Queensland.
“This is a significant breakthrough in the early detection of an often painful and incurable side effect suffered by breast cancer survivors and indeed many other patients recovering from surgeries and a host of other conditions,” she said.
“In fact there are about 300,000 people in Australia with some form of lymphoedema, with worldwide sufferers currently estimated at around 120 million.
“The condition can be irreversible if not detected early.
The early detection and treatment of lymphoedema can make a significant difference in preventing progression to irreversible stages. This can significantly improve the quality of life of patients and that is why there is considerable interest in this technology.”
Ms Bligh said the device was expected to receive FDA clearance this year and was receiving strong support from cancer specialists across the country.
“ImpediMed’s success is a great testament to Queensland’s growing expertise in the area of medical device development,” she said.
“Queensland’s therapeutic medicines and devices sector is an important economic sector for the Smart State.”
ImpediMed is already a leader in the field of bioimpedance to measure shifts in body fluid status for applications such as lymphoedema, oedema and therapeutic dosing.
The company recently acquired the American medical device company Xitron and will now continue the expansion of its design, service and manufacturing sections in the US – which is expected to generate 90 per cent of its future revenue.
ImpediMed has received $115,500 in grant assistance from the Queensland Government.
Contact: Premier’s office 3224 4500
Company contact: ImpediMed, Greg Brown, CEO, AU Mobile +61 408 2811 27, US Mobile +1 858 537 7612